Circulating Tumor Cells Market Size to Surpass US$ 20.3 Bn by 2030

The global circulating tumor cells market size is expected to worth around US$ 20.3 billion by 2030 from valued at US$ 10.4 billion in 2020 and is anticipated to grow at a CAGR of 15.7% from 2021 to 2030.

Growth Factors

 Many potential applications of CTCs in pre-diagnosis, pretreatment, and intra- and post-treatment provide lucrative growth opportunities to players involved in the development of CTC enrichment and isolation products Research organizations are engaged in endeavors aimed at developing CTC-based tests to improve cancer diagnosis in terms of efficiency and speed.

Get the sample copy of report@ https://www.visionresearchreports.com/report/sample/38319

Furthermore, the growing demand for minimally invasive diagnostic procedures is anticipated to propel investments by key stakeholders in this area. CTC-based liquid biopsy tests lead to limited trauma and enable rapid recovery owing to their non-invasive nature. Moreover, it enables minimal invasive screening of tumors before opting for complex surgical procedures, such as radiotherapy, chemotherapy, and surgical removal of tumors, thus positively impacting the adoption.

Report Highlights

The CTC detection and enrichment methods segment accounted for the largest revenue share of 75.8%. The availability of different methods for the enrichment of circulating tumor cells in cancer detection is expected to significantly impact segment growth over the forecast period. Moreover, positive or negative enrichment of circulating tumor cells based on biological properties is expected to hold significant potential for market growth.

An effective enrichment process helps in the enhancement of sensitivity, selectivity, and yield, thereby ensuring successful clinical translation of this field. Different detection techniques include magnetic beads-based enrichment, centrifugal force, filtration, and other physical properties such as size, density, deformity, and electric charges.

Advancements in technologies such as immunofluorescence, NGS, FISH, and qPCR are anticipated to drive the clinical utility of these cells, and thus accelerating revenue growth for CTC analyses. Several companies are investing in the development of products that help in CTC analysis and downstream assays. For instance, Vortex Biosciences offers various CTC analysis products, including immunofluorescence, cytopathology, cytogenetics (FISH), cell culture, and genomics.

 The research segment dominated the market and captured the largest revenue share of 82.8% in 2020. Circulating tumor cells are regarded as a substrate of cancer metastasis. Circulating tumor cells enumeration remains largely a research tool. Recently, the focus has shifted toward circulating tumor cells characterization and isolation, which can provide significant opportunities in predictive testing research.

This arena has significantly improved cancer studies, thus, products offered in the market are primarily designed to be used within research settings. Some key products that have contributed to the large share of research settings are Parsortix Technology, Target Selector Platform, Apostream, Celsee PREP 400, IsoFlux CTC system, DEPArray System, VTX-1, and AdnaTest.

The devices or systems segment dominated the market and accounted for the largest revenue share of 52.8% in 2020. This can be attributed to the presence of a wide portfolio under this category coupled with upcoming advances with regard to microfluidics technology. The introduction of fabricated glass microchips to overcome the challenges and to increase technical completeness for mass production are expected to propel further growth in this segment.

The development of automated instruments that eliminates the use of additional blood collection tubes hampers the revenue growth of blood collection tubes. The reduction in costs is also observed as the transportation is free of the additional laboratory consumables and transfer tubes when the reagent-equipped tubes are used.

The blood specimen segment dominated the market and accounted for the largest revenue share of 56.9% in 2020. A large concentration of these cells in blood samples as compared with other biospecimens is responsible for the largest penetration of this specimen type. Approaches for tumor cells identification in blood samples is considered important in current cancer research, as it aids in the prediction of prognosis and determination of the response to systemic chemotherapy. However, the use of whole blood as a specimen poses a challenge when combined with microfluidic technology.

Membrane clogging as a result of a high concentration of blood cells minimizes the applicability of whole blood samples in microfluidic-based circulating tumor cells enumeration. Devices with various pore shapes and sizes are anticipated to overcome this issue and drive segment growth in the coming years. Moreover, the development of fluid-assisted separation technology by Clinomics, a molecular laboratory based in Bloemfontein, Free State can be employed for efficient detection of these cells.

In 2020, North America dominated the Circulating Tumor Cells (CTCs) market and accounted for the largest revenue share of 61.2%. Advanced Cell Diagnostics; Apocell, Inc.; Aviva Biosciences; Biocept, Inc.; Biofluidica, Inc.; and CellTraffix, Inc are the key players operating in the region. These players are undertaking various strategies to enhance their market hold can be attributed to the large share of the U.S. market.

Furthermore, the presence of a population with high susceptibility to cancer, an increase in market penetration rates, and technologically advanced cancer care infrastructure are some of the key factors accounting for its large share. On the other hand, Asia Pacific is projected to grow at a lucrative rate due to high unmet diagnostic needs coupled with rapidly growing patient awareness with regard to early detection of cancer and risk assessment.

Key Players 

• QIAGEN
• Bio-Techne Corporation
• Precision for Medicine
• AVIVA Biosciences
• BIOCEPT, Inc.
• BioCEP Ltd.
• Fluxion Biosciences, Inc.
• Greiner Bio One International GmbH
• Ikonisys Inc.
• MiltenyiBiotec
• IVDiagnostics
• BioFluidica
• Canopus Bioscience Ltd.
• Biolidics Limited
• CreativMicroTech, Inc.
• LungLife AI, Inc.
• Epic Sciences
• Rarecells Diagnostics
• ScreenCell
• Menarini Silicon Biosystems
• LineaRx, Inc. (Vitatex, Inc.)
• Sysmex Corporation
• STEMCELL Technologies, Inc. 

Market Segmentation

• Technology Outlook 
  • CTC Detection & Enrichment Methods
    • Immunocapture (Label-based)
      • Positive Selection
      • Negative Selection
    • Size-based Separation (Label-free)
      • Membrane-based
      • Microfluidic-based
    • Density-based Separation (Label-free)
    • Combined Methods (Label-free)
  • CTC Direct Detection Methods
    • SERS
    • Microscopy
    • Others
  • CTC Analysis
• Application Outlook
  • Clinical/ Liquid Biopsy
    • Risk Assessment
    • Screening and Monitoring
  • Research
    • Cancer Stem Cell &Tumorogenesis Research
    • Drug/Therapy Development
• Product Outlook
  • Kits & Reagents
  • Blood Collection Tubes
  • Devices or Systems
• Specimen Outlook
  • Blood
  • Bone Marrow
  • Other Body Fluids
• Regional Outlook
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Click Here to View Full Report Table of Contents

Buy this Premium Research Report@ https://www.visionresearchreports.com/report/cart/38319

You can place an order or ask any questions, please feel free to contact at sales@visionresearchreports.com | +1 9197 992 333